Two New Antibodies Keep HIV Undetectable in Trial
A small Columbia University study found an infusion every eight weeks suppressed the virus in most participants for up to six months.
Updated on Nov. 13, 2026 in Sex Life
Live Poll
Would you switch from daily HIV pills to an infusion every eight weeks?
Columbia University researchers presented a study combining two new antibodies that kept HIV undetectable in most participants. The findings were presented at HIV Glasgow 2026 and simultaneously published in The Lancet HIV.
Why it matters
The approach replaces daily HIV medication with periodic infusions, which could change how the virus is managed if later research confirms the results. The study is small and the treatment is experimental, so its broader applicability remains to be tested.
The evidence comes from a small study conducted at six U.S. clinics, where most participants kept the virus suppressed for up to six months after infusions every eight weeks. Longer-term outcomes, broader safety data and results in larger groups have not been reported.
The players
Columbia University
Columbia University is a private Ivy League research university in New York City whose medical researchers led the study.
The details
Participants received intravenous infusions of two antibodies that disrupt the interaction between the virus and cells, replacing their usual daily HIV medication. The treatment remains experimental, and the study's small size limits how far its results can be generalized.
Timeline
Viral suppression in most participants lasted up to six months.
Participants received an antibody infusion once every eight weeks.
The findings were presented at HIV Glasgow 2026 on November 13, 2026.
Health Landscape
The study extends a shift in HIV care away from daily oral pills toward less frequent dosing, following the development of long-acting injectable regimens. Whether antibody-based approaches can join that trend will depend on larger trials and longer follow-up.
For people living with HIV, the study points to a possible future where antibody infusions replace daily pills, though the treatment is not available outside research settings. Anyone managing HIV should continue their current prescribed care until new options are approved.
The takeaway
Antibody infusions every few months are an early signal that HIV treatment may move beyond daily pills, but the evidence is preliminary and limited to a small group. Continued adherence to current medication remains the standard of care.
Further reading
For related coverage of intimacy and health topics, see Sex Life.
Source note: This article includes information reported by EATG.
Live Poll
Would you switch from daily HIV pills to an infusion every eight weeks?
